Navigation Links
1960s-era anti-cancer drug points to treatments for Lou Gehrig's disease
Date:6/13/2012

A long-used anti-cancer drug could be a starting point to develop new treatments for the incurable nerve disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis (ALS), scientists are reporting. Their research showing how the drug prevents clumping of an enzyme linked to ALS appears in the Journal of the American Chemical Society.

Lucia Banci, Ivano Bertini and colleagues explain that ALS causes a progressive loss of muscle control as the nerves that control body movements wither and die. Patients become weak and have difficulty swallowing and breathing, and most die within three to five years of diagnosis. Although some ALS cases are hereditary and run in families, about 90 percent are "sporadic," with the cause unknown. Some research links sporadic ALS to clumping of an antioxidant enzyme called hSOD1. The authors explored whether cisplatin, a chemotherapy drug used since the 1960s that is known to interact with some of the enzyme's amino acids, has any effect on hSOD1 clusters.

The scientists found that in laboratory tests, the anti-cancer drug cisplatin bound readily to the enzyme, preventing hSOD1 from aggregating and dissolving existing bunches. Cisplatin targets sites that can form bonds between hSOD1 after the enzyme loses the atom of copper it normally carries. The scientists note that cisplatin does not prevent the enzyme from performing its normal functions. "From this work it appears that cisplatin is a promising lead compound for the rational design of ALS treatments," the authors say.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
2. More Research Points to Long-Term Ills With Bone Drugs
3. Research With Dogs Points to Early Test for Arthritis
4. Study Pinpoints New Abnormality in Athletes Heart
5. Experimental Chemo Combo for Colon Cancer Disappoints
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
8. Study examines treatments for relieving breathing difficulties among patients with lung effusions
9. Researchers make promising discovery in pursuit of effective lymphoma treatments
10. Research May Point to New Obesity Treatments
11. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology: